<DOC>
	<DOCNO>NCT02089919</DOCNO>
	<brief_summary>Most study cancer stem cell ( CSC ) involve inoculation cell human tumor immunosuppressed mouse , prevent assessment immunologic interaction effect CSCs . In study , investigator examine vaccination effect produce CSC-enriched population histologically distinct murine tumor inoculation different syngeneic immunocompetent host . Enriched CSCs immunogenic effective antigen source unselected tumor cell induce protective antitumor immunity.Immune sera CSC-vaccinated host contain high level IgG bound CSCs , result CSC lysis presence complement.CTLs generate peripheral blood mononuclear cell splenocytes harvest CSC-vaccinated host capable kill CSCs vitro . Mechanistic investigation establish CSC-primed antibody T cell capable selective target CSCs confer anti-tumor immunity .</brief_summary>
	<brief_title>Cancer Stem Cells Vaccine Therapy Treating Hepatocellular Cancer Patients</brief_title>
	<detailed_description>To assess feasibility generate CSC-loaded DC vaccine clinical use , investigator harvest peripheral blood tumor specimen patient hepatocellular cancer . The investigator purify T , B cell generate DCs PBMCs hepatocellular cancer patient.On hand , investigator isolate ALDHhigh ALDHlow tumor cell tumor specimen hepatocellular cancer patient use similar protocol investigator report . Aim 1 : To demonstrate , vitro , relative cellular anti-hepatocellular cancer CSC immunity induce hepatocellular cancer CSC-DC prim cytotoxic T cell . Aim 2 : To determine , vitro , specific bind lysis hepatocellular cancer CSCs antibody produce purified B cell PBMCs stimulate hepatocellular cancer CSC-DC .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Any patient diagnosis HCC base histology current accept radiological measure . 2 . Age &gt; 18 year . 3 . Patient MRI CT result ( positive HCC ) 3 month prior recruitment . 4 . AFP &gt; 30 . 5 . Patient eligible fail HCC treatment . 6 . Karnofsky performance status &gt; 70 % . 7 . The patient show normal organ function accord follow parameter ( measure within six week prior treatment allocation ) : Hemoglobin : Within normal range accord institutional standard ; Absolute leukocyte count : Within normal range accord institutional standard ; Absolute lymphocyte count : Within normal range accord institutional standard ; Platelet count : Within normal range accord institutional standard ; Alanine aminotransferase : ≤ 2.5 x Upper Limit Normal ( ULN ) ; Aspartate aminotransferase : ≤ 2.5 x ULN ; Total bilirubin : ≤ 1.5 x ULN . In case know Gilbert 's syndrome ≤ 2 x ULN ; Serum creatinine : 1.5 x ULN ; Calculated creatinine clearance : &gt; 50 mL/min . 8 . No history autoimmune disease . 9 . Ability understand study protocol willingness sign write informed consent document . 1 . Patients receive anticoagulation therapy . 2 . Patients receive prior gemcitabine radiation therapy liver bed . 3 . Patients receive investigational agent . 4 . Patients know brain metastasis exclude poor prognosis often develop progressive neurological dysfunction would confound evaluation neurological adverse effect . 5 . Uncontrolled concurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 6 . Patients test positive Hepatitis B virus , Hepatitis C virus HIV . 7. level 3 hypertension ; 8. severe coronary disease ; 9. myelosuppression ; 10. respiratory disease ; 11. brain metastasis ; 12. chronic infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>